Article
Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2000
van Kuilenburg A B, Haasjes J, Richel D J, Zoetekouw L, Van Lenthe H, De Abreu R A, Maring J G, Vreken P, van Gennip A H
Abstract excerpt
Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme in the catabolism of 5-fluorouracil (5FU), and it is suggested that patients with a partial deficiency of this enzyme are at risk for developing a severe 5FU-associated toxicity. To evaluate the importance of this specific type of inborn error of pyrimidine metabolism in the etiology of 5FU toxicity, an analysis of the DPD activity, the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.